Jump to content

Talk:Axicabtagene ciloleucel

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia


Different co-stimulatory domain ?

[edit]

[1] says "Both of the approved therapies target CD19, a protein expressed in the surface of lymphoma and leukemia cells. The primary difference between the two products is the co-stimulatory domain. Upon binding CD19, the drugs induce different co-stimulatory signals to activate an immune response." - Could explain with RS. - Rod57 (talk) 14:02, 21 October 2017 (UTC)[reply]

What is the risk eg of CRS

[edit]

Twice the article mentions risk of CRS etc - but what % is the risk, and is it theoretical (based on what) or measured in clinical trials (which) ? - Rod57 (talk) 16:40, 14 December 2017 (UTC)[reply]

There appear to be only 2 other editors besides yourself on this article. You are free to contact them with your inquiry, but will likely be the one to add the % of risk figure to the article.--Quisqualis (talk) 05:49, 15 December 2017 (UTC)[reply]